GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Beneish M-Score

Halberd (Halberd) Beneish M-Score : -85.07 (As of May. 22, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -85.07 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Halberd's Beneish M-Score or its related term are showing as below:

HALB' s Beneish M-Score Range Over the Past 10 Years
Min: -85.07   Med: -85.07   Max: -85.07
Current: -85.07

During the past 3 years, the highest Beneish M-Score of Halberd was -85.07. The lowest was -85.07. And the median was -85.07.


Halberd Beneish M-Score Historical Data

The historical data trend for Halberd's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Beneish M-Score Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Beneish M-Score
- - -85.07

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Beneish M-Score - - -85.07

Competitive Comparison of Halberd's Beneish M-Score

For the Biotechnology subindustry, Halberd's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halberd's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Halberd's Beneish M-Score falls into.



Halberd Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Halberd for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 3+0.404 * 1.4166+0.892 * 0.375+0.115 * 0.8333
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5722+4.679 * -17.75-0.327 * 1.7856
=-85.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jul23) TTM:Last Year (Jul22) TTM:
Total Receivables was $0.00 Mil.
Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Total Current Assets was $0.01 Mil.
Total Assets was $0.01 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $0.15 Mil.
Total Current Liabilities was $0.79 Mil.
Long-Term Debt & Capital Lease Obligation was $0.15 Mil.
Net Income was $-0.45 Mil.
Gross Profit was $0.00 Mil.
Cash Flow from Operations was $-0.24 Mil.
Total Receivables was $0.00 Mil.
Revenue was $0.01 Mil.
Gross Profit was $0.01 Mil.
Total Current Assets was $0.01 Mil.
Total Assets was $0.02 Mil.
Property, Plant and Equipment(Net PPE) was $0.01 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $0.71 Mil.
Total Current Liabilities was $0.60 Mil.
Long-Term Debt & Capital Lease Obligation was $0.15 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0.003) / (0 / 0.008)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.008 / 0.008) / (0.001 / 0.003)
=1 / 0.333333
=3

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.009 + 0.004) / 0.012) / (1 - (0.013 + 0.005) / 0.017)
=-0.083333 / -0.058824
=1.4166

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.003 / 0.008
=0.375

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.001 / (0.001 + 0.005)) / (0.001 / (0.001 + 0.004))
=0.166667 / 0.2
=0.8333

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0.153 / 0.003) / (0.713 / 0.008)
=51 / 89.125
=0.5722

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.15 + 0.789) / 0.012) / ((0.15 + 0.595) / 0.017)
=78.25 / 43.823529
=1.7856

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-0.454 - 0 - -0.241) / 0.012
=-17.75

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Halberd has a M-score of -85.07 suggests that the company is unlikely to be a manipulator.


Halberd Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Halberd's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Halberd (Halberd) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236